The analysis of the test cohort revealed that HGF, Eotaxin/CCL11, MCP-1/CCL2, Rantes/CCL5 were present in significantly lower concentrations in the inflammatory (RR-MS) phase with respect to the progressive MS clinical forms (SP-MS and PP-MS), findings that were confirmed in the validation cohort (Table 3). The gene discussed is CCL11; the disease is myeloid sarcoma.